Download PDF
Thromb Haemost 1972; 28(01): 135-143
DOI: 10.1055/s-0038-1649049
Original Article
Schattauer GmbH

Inhibition of Thromboplastin Activity in Plasma by Aluminosilicate Treatment

Theodore Chenkin
1)   New York University Research Service, Goldwater Memorial Hospital, Welfare Island, New York, and the New York Psychiatric Institute
,
Doris Moses
1   Columbia University College of Physicians and Surgeons, New York, N.Y.
,
James M. Perel
1)   New York University Research Service, Goldwater Memorial Hospital, Welfare Island, New York, and the New York Psychiatric Institute
,
Murray Weiner   *
1   Columbia University College of Physicians and Surgeons, New York, N.Y.
› Author Affiliations
Further Information

Publication History

Publication Date:
24 July 2018 (online)

    Permissions and Reprints

Summary

Permutit, a synthetic aluminosilicate is an ion exchange agent which, on mixing with plasma produces a prolongation of the clotting time, change in pH, and removal of some gamma globulin and alpha and beta lipoprotein. Heat-inactivation of the ion-exchange property of Permutit also eliminates these effects on plasma. Some of these changes also occur on mixing Permutit with extrinsic thromboplastins.

The evidence presented suggests that the prolonged clotting time is not due to the removal of one or more clotting factors from plasma treated with Permutit.

It is concluded that the prolongation of clotting time produced by Permutit treatment of plasma is due to the formation or release of a potent thromboplastin inhibitor.

* Present address: Merrell-National Labs, Cincinnati, Ohio 45215.


 

  • References

  • 1 Bell W. N, and Alton H. G. 1954; A brain extract as a substitute for platelet suspension in the thromboplastin generation test. Nature 174: 880.
    CrossrefPubMedGoogle Scholar
  • 2 Calmon C, and Kressman T. R. E. 1957. Ion Exchangers in Organic and Biochemistry. Inter-science Publishers; New York, N. Y.:
    Google Scholar
  • 3 Chenkin T, and Weiner M. 1965; A comparison of some human clotting abnormalities with the clotting pattern of normal guinea pigs. Experimental Medicine and Surgery 23: 398.
    PubMedGoogle Scholar
  • 4 Goodwin J. F. 1961; Estimation of plasma fibrinogen using sodium sulfite fractionation. Journal of the Michigan State Medical Society 60: 334.
    PubMedGoogle Scholar
  • 5 Koch F. C. 1937. Practical Methods in Biochemistry. William Wood and Company; Baltimore:
    Google Scholar
  • 6 Page R. C, de Beer E. J, and Orr M. L. 1941; Prothrombin studies using Russell Viper Venom. II. The relation of clotting time to prothrombin concentration in human plasma. Journal of Laboratory and Clinical Medicine 27: 197.
    PubMedGoogle Scholar
  • 7 Quick A. J. 1951. The Physiology and Pathology of Hemostasis. Lea and Febiger; Philadelphia, Pennsylvania:
    Google Scholar
  • 8 Shapiro S, Weiner M, Luddecke H. F, Kroc R. L, and White E. J. 1950; A simply prepared, standardized, and relatively stable thromboplastin extract for estimation of prothrombin time. American Heart Journal 40: 766.
    CrossrefPubMedGoogle Scholar
  • 9 Soulier J. P. 1959; A new adsorption agent for coagulation factors. Journal of Clinical Pathology 12: 303.
    CrossrefPubMedGoogle Scholar
  • 10 Weiner M, and Jiminez M. 1956; Significance of clotting tests augmented by heparin. American Journal of Clinical Pathology 26: 243.
    CrossrefPubMedGoogle Scholar